Pfizer and Merck Q2 Preview: New Bets Meet Fading Legacy Sales

Pfizer and Merck face the same day of judgment

Pfizer reports Aug. 4, before market open, and Merck holds its investor call at 9:00 a.m. ET on Tuesday, Aug. 4. That puts both results on the same calendar: investors will see whether these companies are building new growth or merely managing decline better than feared.

Pfizer: can the newer portfolio replace fading sales?

Wall Street is looking for about $14.45 billion in revenue and $0.68 EPS. That is not a heroic bar. The real question is whether the newer part of the business is starting to offset the post-pandemic slide.

The debate is straightforward. Optimists can point to expected strength in the Vyndaqel family, Eliquis, Padcev, and Lorbrena, with Nurtec ODT/Vydura, Cibinqo, Abrysvo, and others also expected to contribute. Skeptics will note that COVID products and Enbrel likely kept dragging. In that context, a simple beat or miss matters less than the quality of the revenue mix.

Merck: Keytruda still matters, but the rest of the portfolio now matters more

Merck comes in with a cleaner surface story. In the first quarter, it reported $16.29 billion of revenue, while Keytruda generated $8.03 billion. That is evidence of real commercial strength, but it also keeps the old bear case alive: too much of the business still rests on one drug.

Merck has also narrowed and raised its full-year sales range to $65.8 billion to $67.0 billion, so expectations are firmer, not easier. Tuesday matters because investors need signs that Keytruda momentum is helping the broader business, not just carrying it.

Pfizer: investors need proof of replacement, not just a beat

Pfizer's setup is simple: investors do not need a headline beat. They need proof that the company is replacing fading pandemic sales with products that have durable demand.

A beat can still miss the point

This is not a high bar. Pfizer is walking into a quarter shaped by a roughly 13% drop in revenue, with expectations around $0.68 per share. Pfizer has also topped earnings estimates in each of the last four quarters, so another beat would not be surprising on its own. The real issue is whether the underlying business is stabilizing.

The mix matters more than the headline number

Pfizer still says it is targeting $59.5 billion to $62.5 billion in full-year revenue. That range is the cleanest scoreboard. It forces management to show whether the non-COVID mix is doing enough to offset the post-pandemic slide. If guidance stays firm and is backed by commercial examples rather than cost-cutting language, that matters. If management starts hedging there, investors should assume the turnaround is still early.

The PADCEV expansion is a visible catalyst

The best recent clue is concrete. The July 10 bladder-cancer approval broadened PADCEV's use, which is the kind of change doctors and payers can act on relatively quickly. It also gives bulls a clearer argument that oncology momentum can help offset COVID weakness.

Cost cuts can support margins, not demand

Pfizer's cost transformation can help margins, but it cannot fix a revenue cliff. The bigger pressure remains the fading COVID contribution. That is why guidance framing matters more than a routine earnings beat, especially with CFO Dave Denton's final earnings call before he departs on August 15 adding extra attention to management's message.

Merck: Keytruda still leads, but depth is the real test

That earlier sales strength gives Merck room to breathe. But Tuesday is still a quality check: is the company adding durable winners, or leaning too heavily on one flagship drug?

Keytruda demand is real

The clearest signal is simple: Keytruda/Keytruda Qlex sales were $8.0 billion, including Keytruda Qlex sales of $128 million. That passes the smell test. A drug still selling at that scale has real clinical and commercial traction, and the subcutaneous format is beginning to contribute.

Winrevair and animal health are the next proof points

This is the part that matters most now. In Q1, WINREVAIR Sales Were $525 Million and Animal Health Sales Were $1.8 Billion. That is not minor background noise. It suggests Merck may finally have more than one thing moving in the right direction.

Winrevair's growth also looks commercially grounded: management tied the increase to broader U.S. use and early launches in Japan and Europe initial rollouts in Japan and Europe drove the increase. Animal health is the kind of steadier, repeat-purchase business that can help smooth the cycle. If those units keep working, Merck looks less like a one-drug story and more like a broader platform.

Bull case vs. bear case

Bulls can argue that Keytruda is still selling strongly sustained growth in 2026, while Winrevair and animal health show the portfolio is broadening. Bears will counter that Keytruda still accounts for about 55% of pharmaceutical sales, and that large deal-related charges can distort the quarter.

Watch three things: - Whether Keytruda growth remains firm. - Whether Winrevair and animal health continue to broaden the revenue base. - Whether management sounds confident in demand, not just in guidance framing.

If the second-wave businesses look durable, Merck can rerate on more than Keytruda loyalty. If not, the market may keep treating it as a mature hero drug with a long shadow.

What decides the trade from here

Tomorrow's prints matter because they determine whether these are genuine turnarounds or just experienced giants managing expectations better than feared. The cleanest approach is to separate commercial truth from presentation skill.

What to watch

• Pfizer: Take the expected roughly 13% drop on the bottom line as background, not the verdict. The real signal is whether management points to fresh commercial wins, including the bladder-cancer approval, as the thing replacing faded COVID sales rather than leaning too heavily on cost cuts or softer wording.
• Merck: Look past the Keytruda headline and check whether Winrevair, animal health, and other launches are becoming real contributors rather than side notes.
• Both companies: Listen for specificity on demand, launch execution, and guidance assumptions.

What would break the bullish view

• Pfizer keeps beating mainly through cost control while the replacement basket still looks too narrow.
• Merck leans too heavily on sustained growth in 2026 for Keytruda while the rest of the portfolio fails to develop into a real second engine.
• Either company sounds more confident in framing than in actual demand.

My stance: stay interested, but don't get too committed until Tuesday's answers pass the smell test.